SPP1Expressed In Pleural Effusion Predicts Survival Of Patients With Advanced Non-small Cell Lung Cancer

Background and Objective Malignant pleural effusion (MPE) is a common complication of advanced lung cancer. It has been validated that SPP1palys a key role in MPE caused by lung cancer metastasis. The aim of this study was to figure out whether the expression of SPP1in MPE might be the prognositic biomarker of Non-small cell lung cancer (NSCLC) patients.Methods A total of85patients suffered from MPE were chosen from the respiratory department of Nanjing General Hospital caused by NSCLC as case group, while24control samples were collected from those benign lung diseases as control group. ELISA were used to detect the contents of SPP1from each specimen. The case group can be divided into SPP1high expression group and SPP1low expression group by the cutoff value from the ROC curve. The survival of all the lung cancer patients were followed up. SPSS16.0statistical analysis software were used for related analysis.Results SPP1in case group are significantly increased than the control group (P<0.01). With a cutoff value of1247.90ng/ml, the diagnostic accuracies of pleural effusion SPP1for malignancy were0.660(95%Cl:0.550-0.770).There is only statistically significant difference between SPP1high expression group and SPP1low expression group in number of extrapulmonary organ of metastasis (P=0.03), Kaplan-Meire survival analysis showed that SPP1expression quantity intimately negative associated with OS and PFS of NSCLC patient (P=0.026and P=0.039, separately). The patient who has lower level of SPP1showed longer survival than those with higher SPP1.SPP1level in MPE may be considered as an independent prognositic factor of NSCLC patients (HR=1.832,95%CI=1.003-3.345;P=0.049).Conclusion Our reselts suggest that SPP1level in MPE do higher than which in benign pleural effusion. The SPP1level in pleural effusion might be used as a diagnositic and prognostic factor in advanced NSCLC patients...